Michael Gelband’s DiaMedica Therapeutics DMAC Stock Holding History

Michael Gelband’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,011	Closed	-$406K	–	1672
2026 Q1	$406K	Buy	+60,011	New	+$476K	﹤0.01%	1240
2025 Q2	–	Sell	-13,343	Closed	-$51K	–	1578
2025 Q1	$51K	Buy	+13,343	New	+$76.3K	﹤0.01%	1370
2021 Q1	–	Sell	-13,160	Closed	-$133K	–	2212
2020 Q4	$133K	Buy	+13,160	New	+$72K	﹤0.01%	1799

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Michael Gelband's DMAC Position: Q2 2026 in Review

Michael Gelband sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 60,011 shares — an estimated $406K sold.

Michael Gelband first reported a position in DMAC in Q4 2020 and held it in 3 quarters. The position peaked at $406K in Q1 2026. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Michael Gelband reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 60,011 DiaMedica Therapeutics shares in Q2 2026, an estimated $406K.
Michael Gelband first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 3 quarters.
Michael Gelband's DiaMedica Therapeutics position peaked at $406K in Q1 2026.
88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.